Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
Biogen
Biogen’s SPINRAZA High-Dose Approval Isn’t a Label Update — It’s a Lifecycle Defense Strategy in a Therapy Area That Is Running Out of Time
The FDA's approval of a high-dose nusinersen regimen looks like a routine label expansion. Read it as a commercial...